On January 19, 2022 Australia’s Therapeutic Goods Administration (TGA) granted provisionally registration for Biocelect Pty Ltd’s (on behalf of Novavax Inc) COVID-19 vaccine NUVAXOVID. This protein sub-unit vaccine is for active immunisation to prevent COVID-19 in individuals 18 years of age and older and is recommended as 2 doses administered 3 weeks apart.
This a protein subunit vaccine administering a set dose of spike-antigen (SARS-CoV-2 rS or NVX-CoV-2373) compared to the genetic vaccines which deliver a genetic code (mRNA or DNA) which will trick the body into manufacturing unknown quantities of foreign spike-protein antigen.
The product has been under evaluation since February 2021
Australia purchased 51 million doses of Novavax and by September 2022 less than 1% has been used!